Contents

Summary i

Zusammenfassung iv

1 Introduction 1

1.1 Pharmacognosy 1
1.2 The sea as a source of natural products. 1
1.2.1 Brominated marine natural products 2
1.3 Marine natural products as drugs 3
1.4 Chemistry of marine sponges of the order Verongida 6
1.4.1 Brominated tyrosine derivatives 6
1.4.2 Biosynthesis of brominated tyrosine metabolites 8
1.4.3 Chemistry of *Ianthella basta* excluding bastadins 10
1.5 Bastadins 12
1.5.1 Bastadin biosynthesis 17
1.5.2 Bastadin synthesis 19
1.5.3 Bastadin bioactivity 19
1.6 Fouling and antifouling 24
1.6.1 Barnacles and antifouling compounds 24
1.7 Human thrombocyte aggregation 26
1.7.1 Mechanism of thrombocyte aggregation 26
1.7.2 Antiaggregatory drugs 27

2 Aims of the present study 31

3 Material and methods 32

3.1 Animal material 32
3.1.1 Collection and storage 32
3.1.2 Taxonomic data 32
3.2 Chromatographic methods 33
3.2.1 Thin layer chromatography 33
3.2.2 Vacuum liquid chromatography 34
3.2.3 Low-pressure liquid chromatography (LC) 35
3.2.4 High-performance Liquid Chromatography (HPLC) 36
3.2.4.1 Analytical HPLC 36
3.2.4.2 Semi-preparative HPLC 37
3.2.4.3 Preparative HPLC 37
3.3 Mass spectroscopy 37
3.3.1 HPLC-MS 38

3.3.2 ESI (Electro Spray Ionization) Mass Spectroscopy 38
3.3.3 Matrix assisted laser desorption/ionisation, MALDI 39
3.3.4 Fast atom bombardment (FAB) 39
3.4 NMR-Spectroscopy 39
3.4.1 Two dimensional NMR spectroscopy 40
3.5 Isolation of secondary metabolites from marine sponges 40
3.5.1 Structure elucidation 41
3.6 Isolation of secondary metabolites from Ianthella basta 41
3.6.1 Extraction 42
3.6.2 Ethyl acetate extract, EtOAc 42
3.6.3 n-Butanol extract, BuOH 43
3.6.4 Hexane extract, Hex 43
3.6.5 Isolation of bastadin-4, -7 and hemibastadin-1 from the ethyl acetate extract. 43
3.6.6 Isolation of bastadin 4 and 9 from the ethyl acetate extract. 44
3.6.7 Isoaltion of bastadin 4 from the hexane extract. 45
3.6.8 Isolation of bastadin 2 and -6 45
3.6.9 Isolation of bastadin-6 47
3.6.10 Isolation of bastadin-3, -10, and -11 47
3.6.11 Isolation of bastadin-7 and -24 48
3.6.12 Isolation of bastadin-16 48
3.6.13 Isolation of (3,5-dibromo-4-methoxyphenyl)acetic acid 49
3.6.14 Isolation of 2-(2',4'-dibromopenoxy)-4,6-dibromophenol (compound 5) 52
3.7 Synthesis of hemibastadin-1 related analogues 54
3.7.1 Synthesis of hembastadin-1, norbromo-hemibastadin-1 (NBHB-1) and 6,6'-dibromohemibastadin-1 (6,6'-DBHB-1) 54
3.7.1.1 [2-Hydroxyimino-3-(4-hydroxyphenyl)]propionic acid (II) 45
3.7.1.2 Methyl-[2-hydroxyimino-3-(4-hydroxyphenyl)]-propionate (III) 55
3.7.1.3 Norbromo-hemibastadin-1 (NBHB-1, IV) 55
3.7.1.4 Bromination of norbromo-hemibastadin-1 (NBHB-1) 56
3.7.2 Synthesis of L-tyrosine-tyramide (XI). 57
3.8 Biological assays 57
3.8.1 Antifouling assay against the barnacle Balanus improvisus 57
3.8.2 Further antifouling tests 59
3.8.2.1 Antibacterial assay against Bacillus sp., Cytophaga sp., Zooshikella sp., and Shewanella sp 59
3.8.2.2 Diatom assay against Amphora coffeaformis 60
3.8.2.3 Attachment of Mytilus edulis 60
3.8.3 Brine shrimp assay 60
3.9 Pharmacological assays 61
3.9.1 Human thrombocyte aggregation 61
3.9.2 ATP-secretion from human thrombocytes 63
3.9.3 Thromboxane formation during thrombocyte aggregation (RIA) 63
3.9.4 Thromboxane receptor binding 64

3.9.5 Cytotoxicity tests 64
3.9.6 Inhibition of different protein kineases 65
3.9.7 Biofilm inhibition and anti-infective assays 67
3.10 Statistical analysis of data 67
3.10.1 Antifouling assay 67
3.10.2 Human thrombocyte aggregation 68
3.11 Laboratory instruments and chemicals 68
3.11.1 Laboratory chemicals 68
3.11.2 Laboratory instruments 69

4 Results 72

4.1 Isolated compounds 72
4.1.1 Bastadin-2 73
4.1.2 Bastadin-3 81
4.1.3 Bastadin-4 85
4.1.4 Bastadin-6 90
4.1.5 Bastadin-7 94
4.1.6 Bastadin-9 98
4.1.7 Bastadin-10 103
4.1.8 Bastadin-11 106
4.1.9 Bastadin-16 108
4.1.10 Hemibastadin-1 112
4.1.11 Bastadin-24 115
4.1.12 (3,5-dibromo-4-methoxyphenyl)acetic acid 128
4.1.13 2-(2',4'-dibromophenoxy)-4,6-dibromophenol (compound 5) 130
4.2 Synthetic bastadin analogues 132
4.2.1 2-[Hydroxyimino-3-(4-hydroxyphenyl)]propionic acid 132
4.2.2 Methyl-[2-hyroxyimino-3-(4-hydroxyphenyl)]propionate 133
4.2.3 Norbromo-hemibastadin-1, NBHB-1 134
4.2.4 Mixture of 2-debromo-hemibastadin-1 (2-DBHB-1) and 2'-debromo-hemibastadin-1 (2'-DBHB-1) 136
4.2.5 Hemibastadin-1 (synthesised) 137
4.2.6 6-Bromo-hemibastadin-1 (6-BHB-1) and 6'-bromo-hemibastadin-1 (6'-BHB-1) 139
4.2.7 6,6'-Dibromo-hemibastadin-1 (6,6'-DBHB-1) 140
4.2.8 L-Tyrosine-tyramide 142
4.3 Antifouling results 144
4.3.1 Screening of brominated compounds against *Balanus improvisus* 144

4.3.2 Brine shrimp assay 154
4.3.3 Screening of brominated diphenyl ethers for further antifouling activities 154
4.3.3.1 Antibacterial screening 155

4.3.3.2 Anti-diatom activities 156
4.3.3.3 Inhibition of Mytilus edulis attachment 156
4.4 Human thrombocyte aggregation results 157
4.4.1 Thrombocyte aggregation, bastadin-16 160
4.4.2 Thromboxane formation, bastadin-16 160
4.4.3 Thrombocyte secretion, bastadin-16 161
4.4.4 Thrombocyte aggregation, norbromo-hemibastadin-1 162
4.4.5 Thromboxane formation, norbromo-hemibastadin-1 162
4.4.6 Thrombocyte secretion, norboro-hemibastadin-1 163
4.4.7 Bastadin-3 and bastadin-11 163
4.4.8 Influence of bastadin-9 and bastadin-11 on the platelet aggregation 165
4.4.9 Influence of other synthesized hemibastadin-1 analogues on the platelet aggregation 166
4.4.10 Studies of binding to the thromboxane A_2 receptor 167
4.5 Cytotoxicity 168
4.6 Protein kinases activity 169
4.7 Biofilm inhibition and antiinfective assays 171

5 Discussion 173

5.1 Isolated compounds 173
5.1.1 Structure elucidation of bastadins 174
5.1.2 Symmetric bastadins and missing aryl-connections 174
5.1.3 Same molecular formula, same MS, but different hemispheres 175
5.1.4 Structure elucidation of bastadin-24 (Section 4.1.11) 176
5.1.5 Structure elucidation and comments to (3,5-dibromo-4-metoxyphenyl)acetic acid (Section 4.1.12) 178
5.2 Synthesis 178
5.3 Antifouling results 180
5.3.1 Antifouling against Balanus improvisus 181
5.3.2 Antifouling against bacterial growth, diatom activity, and mollusc attachment 182
5.4 Human thrombocyte aggregation 184
5.4.1 Aggreagtion studies 184
5.5 Cytotoxicity results 187
5.6 Protein kinase results 188
5.7 Biofilm inhibition and anti-infective assays 189
5.8 Concluding remarks 190

6 References 192

7 Appendix 213

7.1 Bastadin-6 213
7.2 Bastadin-9 214
7.3 Bastadin-11 215
7.4 Hemibastadin-1 216
7.5 (3,5-dibromo-4-methoxyphenyl)acetic acid 218
7.6 List of isolated and synthesized compounds 219

8 Abbreviations 225

Acknowledgements 227

Curriculum vitae 231